XML 27 R17.htm IDEA: XBRL DOCUMENT v3.20.2
Note 9 - Benefit Plans
6 Months Ended
Jun. 30, 2020
Notes to Financial Statements  
Share-based Payment Arrangement [Text Block]

Note 9: Benefit Plans

 

The Company has stock-based employee compensation plans, which are described in the Company’s 2019 Annual Report. The following tables below summarize transactions under the Company’s equity plans for the six months ended June 30, 2020:

 

Stock Options

 

All remaining stock options from prior year issuances were exercised in 2019 leaving no amounts outstanding as of June 30, 2020. The total intrinsic value of stock options exercised for the six months ended June 30, 2020 and 2019 was $0 and $168,225, respectively. The total intrinsic value of outstanding stock options (including exercisable) was $0 and $136,275 at June 30, 2020 and 2019, respectively.

 

Restricted Stock

 

Number of

Shares

  

Weighted

Average Grant-

Date Fair Value

 
         

Balance of shares non-vested as of January 1, 2020

  24,378  $22.75 

Granted

  17,713   21.84 

Vested

  (11,464)  22.13 

Forfeited

  (1,732)  23.04 

Balance of shares non-vested as of June 30, 2020

  28,895  $22.42 

 

In February 2020, the Company granted 5,579 shares of restricted stock to directors pursuant to the 2015 Equity Plan that have a cliff vesting at the end of one year and thus, expensed over that same period. These shares had a grant date market price of $23.50 per share. The total amount of expense for restricted stock grants to directors (including all previous year’s grants) during the six months ended June 30, 2020 and 2019 was $69,378 and $63,039, respectively.

 

For the six months ended June 30, 2020 and 2019, the Company granted 12,134 and 9,932 shares, respectively, of restricted stock to officers that have a cliff vesting at the end of three years. The expense is being recognized over the applicable vesting period. The total amount of expense for restricted stock grants to officers (including all previous year’s grants) during the six months ended June 30, 2020 and 2019 was $67,720 and $105,255, respectively.

 

Restricted Stock Units

 

Performance

Stock Units

  

Weighted

Average Grant-

Date Fair Value

 
         

Balance of shares non-vested as of January 1, 2020

  -  $- 

Granted

  43,700   15.62 

Vested

  -   - 

Forfeited

  -   - 

Balance of shares non-vested as of June 30, 2020

  43,700  $15.62 

 

On March 19, 2020, the Company granted restricted stock units representing 43,700 hypothetical shares of common stock to officers. There are three possible levels of incentive awards: threshold (25%); target (50%); and maximum (100%). The restricted stock units vest based on two financial performance factors over the period from March 19, 2020 to December 31, 2022 (the “Performance Period”). The two performance measurements of the Company (and the weight given to each measurement) applicable to each award level are as follows: (i) Earnings Per Share (50%) and (ii) Return on Average Assets (50%). In determining compensation expense, the fair value of the restricted stock unit awards was determined based on the closing price of the Company’s common stock on the date of grant, which was $15.62 per share. The expense is being recognized over the applicable vesting period. Due to the fact that the measurements cannot be determined at the time of the grant, the Company currently estimates that the most likely outcome is the achievement between the target and maximum levels. If during the Performance Period, additional information becomes available to lead the Company to believe a different level will be achieved for the Performance Period, the Company will reassess the number of units that will vest for the grant and adjust its compensation expense accordingly on a prospective basis. The total amount of expense for restricted stock units during the six months ended June 30, 2020 and 2019 was ($110,259) and $215,764, respectively. Year-to-date credit amounts in 2020 and the decrease from the period in 2019 are due to the reversal of certain accruals related to final performance agreement payouts under previous grants and the reduction of stock price for valuing compensation expense in the current year.

 

Total stock-based compensation expense recognized for the six months ended June 30, 2020 and 2019 was $161,174 and $384,058, respectively. As of June 30, 2020, there was $739,292 of unrecognized compensation expense related to non-vested restricted stock awards, which will be recognized over the remaining vesting period.